Latest Breaking News On - Hyundai bioscience - Page 1 : comparemela.com

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

/PRNewswire/ Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer.

South koreaSoult ukpyolsiJoobin jungMetabolic anticancerHyundai bioscienceLeon lim

Hyundai Bioscience s antiviral for Dengue Fever to enter clinical trials in Brazil

/PRNewswire/ Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided.

Soult ukpyolsiSouth koreaRio de janeiroEstado do rioKim kyungJoobin jungDevelopment of dengueWorld health organizationSouthern brazilHyundai bioscienceNiclosamide based dengueKim kyung ilHyundai bioscience united

Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer | Taiwan News

Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.

South koreaSoult ukpyolsiJin geunHyundai bioscienceJin geun woo

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

/PRNewswire/ South Korea s biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry.

South koreaUnited statesPuerto ricoSoult ukpyolsiRepublic ofSang giCholla buktoJoobin jungHyundai bioscienceSouth americaSoutheast asiaBioscience united statesGlobal marketing managerHealth care amp hospitalsInfection controlMedical pharmaceuticals

STAT Inhibitors Clinical Trial Analysis: Delveinsight Evaluates A Robust Pipeline As 22+ Influential Pharma Players To Set Foot In The Domain

STAT Inhibitors Clinical Trial Analysis: Delveinsight Evaluates A Robust Pipeline As 22+ Influential Pharma Players To Set Foot In The Domain
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkSumitomo pharmaRecludix pharmaOtsuka pharmaceuticaAccendatech united states incMoleculin biotech incNeurobo pharmaceuticalsNeurobo pharmaceuticals incAndroscience corporationDrug administrationSumitomo pharma america incJiangsu hengrui medicine coSumitomo pharma americaClinical trial analysisDelveinsight evaluates